GlysantisTM is a biotechnology company active in pre-clinical research & development of an innovative nanoparticle platform technology with a wide range of biomedical applications.

Our core technology – NanoDendrixTM – is based on highly branched, plant-derived phytoglycogen nanoparticles. NanoDendrixTM is monodisperse, which means that the particles are of a uniform size. NanoDendrixTM nanoparticles are water soluble, biodegradable, non-toxic, and have tunable surface chemistry allowing for desirable modifications.

At Glysantis we are leveraging the NanoDendrixTM platform in biomedical applications classified into three main areas:

  • Immunomodulation
  • Drug delivery
  • Anti-infectives

In addition to in-house laboratory facilities in Ontario, Glysantis has partnerships with commercial research organizations and academic collaborations with researchers from Canadian as well as international universities.